TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21477846
Drug: Activated partial
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated partial thromboplastin time‐adjusted UFH twice daily
Study: 7956336
Drug: Tretinoin cream
Normalized name: Tretinoin Cream
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tretinoin cream (0.025 percent) applied daily for seven months
Study: 3262546
Drug: miocamycin 50
Normalized name: Miocamycin
DrugBank: Miocamycin (DB13287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: miocamycin 50 mg/kg.day
Study: 3262546
Drug: amoxycillin 60
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 60 mg/kg.day
Study: 31317669
Drug: Calcium phosphate
Normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium phosphate (CaP)‐coated SLA surface implants
Study: 31317669
Drug: Conventional SLA
Normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional SLA surface implants
Study: 27690294
Drug: CIK cell
Normalized name: Testone CIK KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIK cell immunotherapy combined with standard TMZ chemoradiotherapy
Study: 22834649
Drug: Transdermal 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 1% testosterone gel (5-7.5 mg/day)
Study: 18046027
Drug: Eltrombopag 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 30 mg
Study: 20735290
Drug: Eltrombopag 75
Normalized name: eltrombopag 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag 75 mg
Study: 10443608
Drug: 40 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/kg rectal acetaminophen
Study: 10443608
Drug: 60 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/kg rectal acetaminophen
Study: 8543705
Drug: Nonbehavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonbehavioral treatment
Study: 7437240
Drug: Lignocaine (L)
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine (L)
Study: 25556611
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 100-800 μg
Study: 21829747
Drug: Gatifloxacin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin (10 mg/kg/day for 3 days)
Study: 21829747
Drug: Ciprofloxacin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (30 mg/kg/day for 3 days in two divided doses)
Study: 17378192
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at Houxi (SI 3), treated once daily for 3 sessions (1 course)
Study: 17378192
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group with Mobike, 7.5 mg once daily
Study: 17010857
Drug: Aspiration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration of lens epithelial cells (LECs) from under the anterior capsule
Study: 10522582
Drug: Combined diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined diltiazem (0.2 mg x kg(‐1)) and lidocaine (1.0 mg x kg(‐1))
Study: 10522582
Drug: Diltiazem (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (0.2 mg x kg(‐1))
Study: 10522582
Drug: Lidocaine (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.0 mg x kg(‐1))
Study: 8542008
Drug: Prednisone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (2 mg/kg to a maximum of 60 mg)
Study: 1931867
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin tertile 1
Study: 1931867
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin tertile 2
Study: 1931867
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin tertile 3
Study: 7046104
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (A-CA) 250 mg/125 mg, taken 3 times daily for 7 days
Study: 7046104
Drug: Amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin 250 mg capsules, taken 3 times daily for 7 days
Study: 7046104
Drug: Amoxycillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanic acid (A-CA) after treatment failure on amoxycillin
Study: 28161079
Drug: Active RFc
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active RFc therapy (90 J/cm2)
Study: 28161079
Drug: Sham RFc
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham RFc therapy (1 J/cm2)
Study: 25599275
Drug: 1000 g
Normalized name: MENTHOL 80 g in 1000 g TOPICAL GEL [ACTIVICE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 g fish and mussels/week for 26 weeks (50 μg selenium/day)
Study: 21110034
Drug: Randomized music
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized music therapy (classical, relaxing modern, smooth jazz)
Study: 16798785
Drug: 0.03% tacrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% tacrolimus ointment (TAC-O)
Study: 16798785
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone acetate (HA) and 0.1% hydrocortisone butyrate ointment (HC-O)
Study: 11819709
Drug: Moxibustion with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion with herbal medicine
Study: 8473676
Drug: Combination TAO
Normalized name: troleandomycin
DrugBank: Troleandomycin (DB13179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination TAO and methylprednisolone (MPn)
Study: 8473676
Drug: Combination TAO
Normalized name: troleandomycin
DrugBank: Troleandomycin (DB13179)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination TAO and prednisone
Study: 3936866
Drug: Sandoglobulin (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandoglobulin (12 g as a 3% solution on day 0, day 5, and day 12, total of 36 g)
Study: 27292543
Drug: Timed bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timed bright light therapy
Study: 27292543
Drug: Both timed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both timed bright light therapy and bedtime melatonin
Study: 21039348
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (2 mg) twice per day
Study: 16372264
Drug: Vaccine candidate
Normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine candidate genes OmpA and FepA
Study: 6415987
Drug: Oral metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metoclopramide from day 1 to 6
Study: 6415987
Drug: Bromocriptine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine treatment from day 1 to 3
Study: 31529295
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (200 μgr daily for 1 year)
Study: 24560477
Drug: Buccal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Buccal misoprostol (400 mcg)
Study: 22412143
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice a day with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Study: 22412143
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with capecitabine 1,000 mg/m(2) orally twice a day for days 1 to 14 of every 21-day cycle
Study: 22412143
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg orally twice a day
Study: 16234523
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (vincristine, cisplatin, cyclophosphamide, and etoposide)
Study: 16234523
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (vincristine, carboplatin, ifosfamide, and etoposide)
Study: 16234523
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (both regimens)
Study: 7523131
Drug: Prednisone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (5 mg 4 times daily)
Study: 7523131
Drug: Flutamide (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flutamide (250 mg 3 times daily)
Study: 7523131
Drug: Estramustine phosphate
Normalized name: Estramustine phosphate
DrugBank: Estramustine phosphate (DB14674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estramustine phosphate (280 mg 2-3 times daily)
Study: 7523131
Drug: Epirubicin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (100 mg/m2 i.v. every 3rd week)
Study: 7523131
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (all drugs)
Study: 61389
Drug: Methandienone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methandienone (100 mg/day for 6 weeks)
Study: 25772701
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg preoperatively and 200 mg postoperatively on the day of surgery, continued at 200 mg three times daily for two days.
Study: 11168342
Drug: n-3 polyunsaturated
Normalized name: Omega-3 (n-3) polyunsaturated fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 polyunsaturated fatty acid supplementation (2.08 g for 21 days)
Study: 9294377
Drug: Amphetamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine treatment for 15 months
Study: 9294377
Drug: Amphetamine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine treatment
Study: 25759106
Drug: Hydration with
Normalized name: Gold Bond Healing Hydration with Aloe Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydration with isotonic saline (1 ml/kg/h since the beginning of the procedure and for 24 hours after it)
Study: 21734179
Drug: 4-aminopyridine (4AP)
DrugBank: Dalfampridine (DB06637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-aminopyridine (4AP) 5 mg 3 times daily
Study: 10486353
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg twice daily for 24 months
Study: 10486353
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily for 24 months
Study: 2006663
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and methyldopa
Study: 7168635
Drug: Short term
Normalized name: Short Term Oral Swab System KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short term prophylaxis with a single intravenous dose of tobramycin and lincomycin
Study: 31352415
Drug: Postextubation medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postextubation medical therapy (azithromycin 250 mg and budesonide 0.5 mg for 14 days)
Study: 31352415
Drug: Postextubation medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postextubation medical therapy (azithromycin and inhaled budesonide)
Study: 28069467
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of pantoprazole twice daily and diet changes for 3 months
Study: 28069467
Drug: Treatment (pantoprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (pantoprazole and diet changes)
Study: 21498312
Drug: Body weight-adapted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-adapted CM injection protocol (0.9 mL CM (370 mg I/mL) per kg during 12 s resulting in a constant injection dose rate of 28 mg I/kg/s)
Study: 21498312
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose CM injection protocol (65 mL CM (370 mg I/mL) at 5 mL/s)
Study: 10925979
Drug: 500‐mg Rowasa
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500‐mg Rowasa (mesalamine) suppository
Study: 8923784
Drug: Regimen I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen I: 400 mg of MST-16 combined with 25 mg of VP-16 administered daily
Study: 8923784
Drug: Regimen II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen II: 400 mg of MST-16 combined with 25 mg of VP-16 administered intermittently (3 days a week or every other day)
Study: 1376177
Drug: i.v. polyimmune
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. polyimmune gammaglobulin (500 mg/kg) within 3 days of transplant with 250 mg/kg at weeks 1, 2, 4, and 6
Study: 1376177
Drug: Monoclonal anti‐CD‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal anti‐CD‐3 therapy
Study: 6377851
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 40 mg of mixed gangliosides for ALS for six months
Study: 6377851
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 40 mg of mixed gangliosides for diabetic neuropathy for three months
Study: 29140142
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (0.09 g·kg‐1)
Study: 29140142
Drug: Decaffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decaffeinated coffee (0.09 g·kg‐1)
Study: 20386344
Drug: E2 alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 alone (transdermal E2 0.72 mg for 2 days)
Study: 20386344
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + DNG (E2 0.72 mg + DNG 2 mg/d for 1 week)
Study: 20386344
Drug: E2 +
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: E2 + MPA (E2 0.72 mg + MPA 2.5 mg/d for 1 week)
Study: 14602753
Drug: r-hGH (0.067
Approvals — FDA: no, EMA: no, PMDA: no
Description: r-hGH (0.067 mg/kg.d)
Study: 9408810
Drug: Olanzapine 10
Normalized name: olanzapine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine 10 mg/day or 1 mg/day
Study: 8329024
Drug: CB0006 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB0006 at 0.1 mg/kg
Study: 8329024
Drug: CB0006 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB0006 at 1 mg/kg
Study: 8329024
Drug: CB0006 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CB0006 at 5 mg/kg
Study: 4036826
Drug: Dipyridamole infusion
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole infusion (0.14 mg/kg/min for 4 minutes)
Study: 24814231
Drug: IN dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN dexmedetomidine (1 μg/kg) with midazolam premedication
Study: 24814231
Drug: IN fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN fentanyl (2 μg/kg) with midazolam premedication
Study: 24814231
Drug: IN dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IN dexmedetomidine (1 μg/kg) without premedication
Study: 24814231
Drug: IN fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IN fentanyl (2 μg/kg) without premedication
Study: 19076177
Drug: Immediate/early loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate/early loading of zygomatic implants
Study: 19076177
Drug: Regular implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular implants
Study: 18441038
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (9 minutes of electrical stimulation on the dorsiflexor muscles and 15 minutes of inhibitory Bobath techniques)
Study: 16160622
Drug: Aripiprazole (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (initial dose 2 mg/d, titrated to 5, 10, or 15 mg/d)
Study: 12969190
Drug: IFN TIW
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN TIW (5 MU thrice weekly for 8 weeks followed by 3 MU TIW for 40 weeks)
Study: 12969190
Drug: IFN QD
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN QD (5 MU daily for 8 weeks followed by 3 MU QD for 16 weeks followed by 3 MU TIW for 24 weeks)
Study: 10397076
Drug: BCAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCAA treatment (200 ml of BCAA-rich solution daily for 7 days)
Study: 10397076
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH; protirelin)
Study: 19633850
Drug: PI-88 delivered
Normalized name: Heparanase inhibitor PI-88
DrugBank: Muparfostat (DB05808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PI-88 delivered subcutaneously (SC) at doses ranging from 80 to 315 mg
Study: 18451646
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg once daily for 2 weeks
Study: 10993128
Drug: Clomipramine (50-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine (50-150 mg)
Study: 9126791
Drug: Hepatitis G
Normalized name: Hepatitis G antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis G virus infection
Study: 9126791
Drug: Hepatitis G
Normalized name: Hepatitis G antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis G virus positive patients
Study: 1541312
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets once daily (o.m.)
Study: 1541312
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets twice daily (b.d.)
Study: 1541312
Drug: Plain tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain tablets twice daily (b.d.)
Study: 1541312
Drug: Extended release
Normalized name: Tylenol Extended Release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended release tablets
Study: 3157887
Drug: Capillary protective
Normalized name: Artemisia capillaris leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capillary protective drug derived from rutin
Study: 30846294
Drug: Ablative fractional
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative fractional CO2 laser (AFCO2L) treatment
Study: 26811679
Drug: Paliperidone-ER (3-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paliperidone-ER (3-12 mg/day)
Study: 20441572
Drug: Diabetes-specific cognitive
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes-specific cognitive behavioural therapy adapted for the elderly
Study: 20441572
Drug: Intensified treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified treatment as usual
Study: 20441572
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment conditions after 12 weeks
Study: 12139152
Drug: Oral vaccine
Normalized name: RotaTeq Oral Vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vaccine prepared from insect saliva
Study: 12139152
Drug: Placebo (stable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (stable vaccine solvent)
Study: 9923552
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/m2 per day plus LV 90 mg per day in three divided doses every 8 h for 28 days
Study: 9923552
Drug: Oral LV
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral LV 30 mg plus UFT 200 mg
Study: 8635038
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (r‐HuEPO) administered subcutaneously at a dose of 150 U/kg three times per week for 6 weeks; in nonresponders, the dose was doubled for the subsequent 6 weeks.
Study: 1871856
Drug: CyA monotherapy
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA monotherapy
Study: 6352600
Drug: Azlocillin at
Normalized name: azlocillin
DrugBank: Azlocillin (DB01061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azlocillin at 18 g/day for a mean of 13 days
Study: 6352600
Drug: Gentamicin at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin at 180 mg/day for a mean of 11 days
Study: 30277424
Drug: Anchored to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anchored to a four-times-daily treatment regimen
Study: 29735964
Drug: Thunder-fire moxibustion
Normalized name: Fire Out
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thunder-fire moxibustion therapy combined with calcium carbonate D3
Study: 17609305
Drug: Ablative target-absorbed
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ablative target-absorbed dose of 200 Gy (n = 78)
Study: 17609305
Drug: Nonablative doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonablative doses of 100 or 120 Gy (n = 99)
Study: 15640479
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 99 mg isoflavones/d
Study: 15640479
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 99 mg isoflavones/d (in equol producers)
Study: 15640479
Drug: Soy protein
Normalized name: Soy Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy protein containing 99 mg isoflavones/d (in equol nonproducers)
Study: 8789590
Drug: Pizotifen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pizotifen (1 mg orally, administered 5 hours before exercise)
Study: 31415381
Drug: Qingzhong (TDF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingzhong (TDF) 300mg once daily for 48 weeks
Study: 31415381
Drug: Viread (TDF)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Viread (TDF) 300mg once daily for 48 weeks